The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Open accessAbstract
BACKGROUND: The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies. METHODS: This multicenter, randomized, partially double-blind trial used a factorial design to compare pairs of sequential three-drug regimens, starting with a regimen including zidovudine and lamivudine or a regimen including didanosine and stavudine in combination with either nelfinavir or efavirenz. The primary end point was the length of time to the failure of the second three-drug regimen. RESULTS: A total of 620 subjects who had not previously received antiretroviral therapy were followed for a median of 2.3 years. Starting with a three-drug regimen containing efavirenz combined with zidovudine and lamivudine (but not efavirenz combined with didanosine and stavudine) appeared to delay the failure of the second regimen, as compared with starting with a regimen containing nelfinavir (hazard ratio for failure of the second regimen, 0.71; 95 percent confidence interval, 0.48 to 1.06), as well as to delay the second virologic failure (hazard ratio, 0.56; 95 percent confidence interval, 0.29 to 1.09), and significantly delayed the failure of the first regimen (hazard ratio, 0.39) and the first virologic failure (hazard ratio, 0.34). Starting with zidovudine and lamivudine combined with efavirenz (but not zidovudine and lamivudine combined with nelfinavir) appeared to delay the failure of the second regimen, as compared with starting with didanosine and stavudine (hazard ratio, 0.68), and significantly delayed both the first and the second virologic failures (hazard ratio for the first virologic failure, 0.39; hazard ratio for the second virologic failure, 0.47), as well as the failure of the first regimen (hazard ratio, 0.35). The initial use of zidovudine, lamivudine, and efavirenz resulted in a shorter time to viral suppression. CONCLUSIONS: The efficacy of antiretroviral drugs depends on how they are combined. The combination of zidovudine, lamivudine, and efavirenz is superior to the other antiretroviral regimens used as initial therapy in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Brinkman, K., Smeitink, J. A., Romijn, J. A., & Reiss, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06102-4 · Cited by 866
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Self-citationChanges in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573
Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 367
Boucher, C. A., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M. A., & Cameron, J. M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.10.2231 · Cited by 313
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Paredes, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.8.1123 · Cited by 235
Shafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., Johnson, V. A., Morse, G. D., Nokta, M. A., Martinez, A. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030265 · Cited by 228
Self-citationWalker, U. A., Setzer, B., & Venhoff, N. (2002) · AIDS · doi:10.1097/00002030-200211080-00009 · Cited by 213
3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Meibohm, A., Condra, J. H., Valentine, F. T., McMahon, D., Gonzalez, C., Jonas, L., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00007 · Cited by 204
Grabar, S., Pradier, C., Le Corfec, E., Lancar, R., Allavena, C., Bentata, M., Berlureau, P., Dupont, C., Fabbro-Peray, P., Poizot-Martin, I., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00009 · Cited by 175
Ickovics, J. R., Cameron, A. E., Zackin, R. A., Bassett, R. L., Chesney, M. A., Johnson, V. A., Kuritzkes, D. R., A Team, Acosta, E. P., Barnett, R. L., et al. (2002) · Antiviral Therapy · doi:10.1177/135965350200700308 · Cited by 128
Self-citationAn Introduction to Nucleoside and Nucleotide Analogues
Squires, K. (2001) · Antiviral Therapy · doi:10.1177/135965350100603s01 · Cited by 84
Gallego, O., de Mendoza, C., Pérez-Elías, M. J., Guardiola, J. M., Pedreira, J. D., Dalmau, D., González, J., Moreno, A. M., Arribas, J. R., Rubio, A., et al. (2001) · AIDS · doi:10.1097/00002030-200109070-00014 · Cited by 68
(2003) · HIV Medicine · doi:10.1046/j.1468-1293.4.s1.3.x · Cited by 56
ACTG (AIDS Clinical Trials Group) 384
Smeaton, L. M., DeGruttola, V. G., Robbins, G. K., & Shafer, R. W. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00126-4 · Cited by 34
Self-citation
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationTenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Self-citation
Metadata
- Authors
- Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dubé, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., Gedeon, L., van der Horst, C., Murphy, R. L., Becker, M. I., D'Aquila, R. T., Vella, S., Merigan, T. C., & Hirsch, M. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-11
- Volume
- 349
- Issue
- 24
- Pages
- 2293-2303
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015796602
- Cited by
- 351
- References
- 21
- FWCI
- 24.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.